Ionis Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of a Pending Investigation Into Ionis Pharmaceuticals (IONS)

Ionis Pharmaceuticals told investors its CARDIO-TTRansform program was on track to deliver landmark data -- then the Phase-3 trial missed its primary endpoint. Levi & Korsinsky is investigating.

Ionis Pharmaceuticals (NASDAQ: IONS) shares were falling more than 20% on July 9, 2026, after the Company disclosed that its Phase-3 CARDIO-TTRansform trial failed to meet its primary endpoint. If you purchased IONS shares and suffered a loss, you are encouraged to click here to submit your information. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

The investigation concerns whether the Company's prior public statements regarding the CARDIO-TTRansform program aligned with the trial's ultimate outcome. On November 6, 2024, CEO Brett Monia stated on the Company's Q3 2024 earnings call that the "ongoing CARDIO-TTRansform trial [was] on track to deliver the most comprehensive dataset in these patients in the second half of 2026." More recently, on June 10, 2026, CEO Monia reiterating that data was expected in the back half of the year, told investors "everything is going very well in the conduct of the study and the execution. The study is reasonably derisked for its primary endpoint. We're excited."

On July 9, 2026, the company disclosed that its trial, partnered with AstraZeneca, did not meet its primary endpoint of reducing combined cardiovascular death and recurrent events in transthyretin-mediated amyloid cardiomyopathy patients. The stock opened down more than 20% on the news. Levi & Korsinsky is investigating potential securities law violations on behalf of IONS investors. Shareholders who lost money on IONS are encouraged to contact the firm to discuss their legal rights. You may also reach Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.